Cidara Therapeutics (NASDAQ:CDTX) has received a consensus rating of “Buy” from the ten research firms that are covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $14.18.
Several analysts have commented on the stock. Cantor Fitzgerald set a $15.00 price target on shares of Cidara Therapeutics and gave the stock a “buy” rating in a research note on Thursday, March 8th. Zacks Investment Research cut shares of Cidara Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, January 12th.
Several institutional investors have recently bought and sold shares of CDTX. Raymond James Financial Services Advisors Inc. increased its holdings in shares of Cidara Therapeutics by 37.2% in the 3rd quarter. Raymond James Financial Services Advisors Inc. now owns 23,985 shares of the biotechnology company’s stock worth $194,000 after buying an additional 6,500 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Cidara Therapeutics by 77.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 41,266 shares of the biotechnology company’s stock worth $328,000 after buying an additional 18,001 shares during the last quarter. OxFORD Asset Management LLP increased its holdings in shares of Cidara Therapeutics by 69.1% in the 3rd quarter. OxFORD Asset Management LLP now owns 22,181 shares of the biotechnology company’s stock worth $187,000 after buying an additional 9,065 shares during the last quarter. Eversept Partners LLC bought a new stake in shares of Cidara Therapeutics in the 4th quarter worth about $340,000. Finally, Broadfin Capital LLC increased its holdings in shares of Cidara Therapeutics by 4.5% in the 4th quarter. Broadfin Capital LLC now owns 857,397 shares of the biotechnology company’s stock worth $5,830,000 after buying an additional 36,994 shares during the last quarter. Hedge funds and other institutional investors own 71.87% of the company’s stock.
Shares of CDTX stock opened at $3.85 on Thursday. Cidara Therapeutics has a 52 week low of $3.75 and a 52 week high of $8.80. The company has a debt-to-equity ratio of 0.12, a quick ratio of 6.43 and a current ratio of 6.43.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Tuesday, February 27th. The biotechnology company reported ($0.69) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.05. analysts predict that Cidara Therapeutics will post -2.66 earnings per share for the current year.
WARNING: “Analysts Set Cidara Therapeutics (CDTX) Target Price at $14.18” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/analysts-set-cidara-therapeutics-cdtx-target-price-at-14-18.html.
About Cidara Therapeutics
Cidara Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of anti-infectives for the treatment of diseases. Its lead product candidate is rezafungin acetate, a molecule in the echinocandin class of antifungals for the treatment and prevention of serious invasive fungal infections, including candidemia and invasive candidiasis, fungal infections associated with high mortality rates.
Receive News & Ratings for Cidara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.